. 2020 Sep 19;12(9):2679. doi: 10.3390/cancers12092679

Table 1.

Phase 3 adjuvant therapeutic trials in stage III colorectal cancer. DFS: disease-free survival; OS: overall survival.

First Author	Study Name	N	Year	Stage	Chemotherapy	Duration	DFS				OS
							3–year DFS	5–year DFS	HR	p	3–year OS	5–year OS	HR	p
IMPACT [11]	IMPACT	652	1982–1989	III	FULV	6 months	62%		0.55	< 10⁻⁴	76%		0.71	0.02
IMPACT [11]					Surgery alone		44%				64%
Francini et al. [13]		118	1985–1990	III	FULV	12 months						69%		0.0025
					Surgery alone							43%
O Connell et al. [14]		317	1988–1989	II–III	FULV	6 months		74%						0.01
O Connell et al. [14]					Surgery alone			58%
André et al. [15]		905	1996–1999	II–III	LV5FU2	6/9 months	73%		1.04	0.7	86%		1.26	0.18
André et al. [15]					FULV	6/9 months	72%				88%
Twelves et al. [16]	X-ACT	1987	1998–2001	III	Capecitabine	6 months	64%		0.87	0.12	81%		0.84	0.07
Twelves et al. [16]					FULV	6 months	61%				78%
André et al. [4]	MOSAIC	2246	1998–2001	II–III	FOLFOX	6 months	78%		0.76	0.002	88%		0.90
André et al. [4]					LV5FU2	6 months	73%				87%
Ychou et al. [23]	FNCLCC Accord02 /FFCD9802	400	1998–2002	III	FOLFIRI	6 months	51%		1.19	0.22		61%	1.20	0.26
Ychou et al. [23]					LV5FU2	6 months	60%					67%
Popov et al. [29]	PETACC-1	1921	1999	III	Raltitrexed	6 months						62%	1.04
Popov et al. [29]					FU/LV	6 months						62%
Saltz et al. [22]	CALGB 89803	1264	1999–2001	III	CPT-11 + FU/LV	8 months	66%	59%		0.85	80%	68%		0.74
Saltz et al. [22]					FU/LV	8 months	69%	61%			81%	71%
Kuebler et al. [17] Yothers et al. [18]	NSABP C-07	2409	2000–2002	II–III	FLOX	6 months		69%	0.82	0.002		80%	0.88	0.08
Kuebler et al. [17] Yothers et al. [18]					FULV	6 months		64%				78%		0.09
Van Cutsem et al. [24]	PETACC-3	2094	2000–2002	III	FOLFIRI	6 months		57%	0.9	0.1		74%
Van Cutsem et al. [24]					LV5FU2	6 months		54%				71%
Haller et al. [19]	XELOXA	1886	2003–2004	III	XELOX	6 months		66%	0.80	0.004		78%	0.87	0.15
Haller et al. [19]					FU/FA	6 months		60%				74%
Allegra et al. [20]	NSABP C-08	2672	2004–2006	II–III	FOLFOX + bevacizumab	FOLFOX 6 months Bevacizumab 1 year	77%		0.89	0.15		82%	0.95	0.56
Allegra et al. [20]					FOLFOX	6 months	75%					81%
De Gramont et al. [26]	AVANT	2867	2004–2007	III	FOLFOX +Bevacizumab	6 months 1 year	73%		1.17	0.07		81%	1.27	0.02
					CAPOX + Bevacizumab	6 months 1 year	75%		1.07	0.44		82%	1.15	0.21
					FOLFOX		76%					85%
Alberts et al. [21]	NCCTG NO147	1863 (KRAS WT)	2004–2009	III	FOLFOX + cetuximab	6 months	71%		1.21	0.08	86%		1.25	0.15
Alberts et al. [21]					FOLFOX	6 months	75%				87%
Taieb et al. [25]	PETACC-8	1602 (KRAS WT)	2005–2009	III	FOLFOX + cetuximab	6 months	75%		1.05	0.66	88%		1.09	0.56
Taieb et al. [25]					FOLFOX	6 months	78%				90%
Kerr et al. [27]	QUASAR,2	1941	2005–2010	II–III	Capecitabine +Bevacizumab	6 months 1 year	75%		1.06	0.54	87%		1.11	0.33
Kerr et al. [27]					Capecitabine	6 months	78%				89%
Grothey et al. [7] Sobrero et al. [33]	IDEA	12834	2007–2015	III	FOLFOX/CAPOX	3 months	75%		1.07	0.11		82%	1.02	0.64
Grothey et al. [7] Sobrero et al. [33]					FOLFOX/CAPOX	6 months	75%					83%